PIRPROFEN

Details

Stereochemistry	RACEMIC
Molecular Formula	C13H14ClNO2
Molecular Weight	251.709
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C(O)=O)C1=CC(Cl)=C(C=C1)N2CC=CC2

InChI

InChIKey=PIDSZXPFGCURGN-UHFFFAOYSA-N

InChI=1S/C13H14ClNO2/c1-9(13(16)17)10-4-5-12(11(14)8-10)15-6-2-3-7-15/h2-5,8-9H,6-7H2,1H3,(H,16,17)

HIDE SMILES / InChI

Description
Sources: https://books.google.ru/books?id=leVCukUgNlsC&pg=PA188&lpg=PA188&dq=PIRPROFEN retrieved from Consolidated List of Products Whose Consumption and or Sale Have Been Banned Withdrawn Severely Restricted or Not Approved By Governments: Chemicals. By United Nations, p.188 | https://www.ncbi.nlm.nih.gov/pubmed/6360612 | https://www.ncbi.nlm.nih.gov/pubmed/3539573

Pirprofen is a non-steroidal anti-inflammatory drug, related structurally to drugs such as ibuprofen, ketoprofen and naproxen. Pirprofen was introduced by Ciba-Geigy in 1982 as a treatment for rheumatic diseases. In 1990 due to adverse effects, including some cases of fatal liver toxicity the manufacturers decided to discontinue marketing it worldwide. Pirprofen proved to be useful in the management of both rheumatoid arthritis and osteoarthritis and as an analgesic. In doses of 600-800 mg/d, pirprofen has been found to be as effective as, but not superior to, aspirin 3.6 g/d in relieving the more common symptoms of rheumatoid arthritis. Pirprofen is as effective as, but not superior to, other available NSAIDs in terms of efficacy, tolerability, and incidence of adverse effects. The recommended dosage in osteoarthritis is 450-600 mg/d.

Originator

Approval Year

PubMed

Title	Date	PubMed
[Hepatitis due to pirprofen; 3 cases, 1 fatality].	1986 Jan-Feb	2938537
Aldosterone glucuronidation by human liver and kidney microsomes and recombinant UDP-glucuronosyltransferases: inhibition by NSAIDs.	2009 Sep	19740398

Patents

Sample Use Guides

In Vivo Use Guide

Published clinical trials indicate that pirprofen 600 to 1200 mg/day as 2 or 3 divided doses is a suitable alternative to usual therapeutic dosages of aspirin, flurbiprofen, ibuprofen, indomethacin, ketoprofen, naproxen, piroxicam and sulindac in the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, musculoskeletal disorders and non-articular rheumatism. In patients with acute postsurgical, trauma or cancer pain, single oral or intramuscular doses of pirprofen 200 to 400mg provide equivalent analgesic activity to usual therapeutic doses of aspirin, diflunisal, ketoprofen, noramidopyrine, paracetamol and pentazocine.

Route of Administration: Other

In Vitro Use Guide

The compound proved to be a potent inhibitor with a Ki value of about 1.2 uM.

Name

Type

Language

PIRPROFEN

Official Name

English

PIRPROFEN [MI]

Common Name

English

RANGASIL 400

Common Name

English

3-Chloro-4-(3-pyrrolin-1-yl)hydratropic acid

Systematic Name

English

SU 21524

Code

English

RACEMIC PIRPROFEN

Common Name

English

SU-21524

Code

English

2-(3-CHLORO-4-(2,5-DIHYDROPYRROL-1-YL)-PHENYL)PROPANOIC ACID

Systematic Name

English

2-(3-CHLORO-4-(3-PYRROLIN-1-YL)PHENYL)PROPIONIC ACID

Systematic Name

English

PIRPROFEN [USAN]

Common Name

English

Pirprofen [WHO-DD]

Common Name

English

BENZENEACETIC ACID, 3-CHLORO-4-(2,5-DIHYDRO-1H-PYRROL-1-YL)-.ALPHA.-METHYL-

Common Name

English

RENGASIL

Common Name

English

(±)-PIRPROFEN

Common Name

English

HYDRATROPIC ACID, 3-CHLORO-4-(3-PYRROLIN-1-YL)-

Common Name

English

pirprofen [INN]

Common Name

English

PIRPROFEN [MART.]

Common Name

English

SEFLENYL

Brand Name

English

PIRPROFEN [JAN]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QM01AE08